# A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

> **NCT05816252** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Klus Pharma Inc.** · enrollment: 356 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SKB264
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05816252
- **Lead sponsor:** Klus Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05816252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05816252, "A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05816252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*